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Epidermal growth factor receptors (ErbB1–4) are
oncogenic receptor tyrosine kinases (RTKs) that
regulate diverse cellular processes. In this study, we
combine measurement and mathematical modeling
to quantify phospho-turnover at ErbB receptors in
human cells and to determine the consequences for
signaling and drug binding. We find that phospho-
tyrosine residues on ErbB1 have half-lives of a few
seconds and therefore turn over 100–1000 times in
the course of a typical immediate-early response to
ligand. Rapid phospho-turnover is also observed for
EGF-activated ErbB2 and ErbB3, unrelated RTKs,
and multiple intracellular adaptor proteins and sig-
naling kinases. Thus, the complexes formed on the
cytoplasmic tail of active receptors and the down-
stream signaling kinases they control are highly
dynamic and antagonized by potent phosphatases.
We develop a kinetic scheme for binding of anti-
ErbB1 drugs to receptors and show that rapid
phospho-turnover significantly impacts their mecha-
nisms of action.
INTRODUCTION
The epidermal growth factor receptor (ErbB1/EGFR) is a proto-
typical receptor tyrosine kinase (RTK) that activates multikinase
phosphorylation cascades and regulates diverse cellular
processes including proliferation, migration, and differentiation
(Citri and Yarden, 2006). Differential binding of 13 known extra-
cellular ligands to ErbB1–4 receptors induces formation of
homo- and hetero-oligomers. In the case of ErbB1, whose struc-
ture has been studied in detail, ligand binding is thought to
promote a conformational switch that positions the C-terminal
cytoplasmic tail of one receptor near the activation loop of the
other, thereby facilitating phosphorylation in trans (Zhang et al.,Molec2006). Receptor dimers can form in the absence of ligand but
the switch to an active conformation probably occurs only
upon ligand binding (Chung et al., 2010). In solid tumors ErbB
receptors are frequently mutated, overexpressed or activated
by autocrine or paracrine ligands (Holbro and Hynes, 2004),
and multiple small molecule kinase inhibitors and therapeutic
antibodies targeting ErbB receptors are in clinical use (Tables
S1 and S2). In many cases, the reasons for the differential effec-
tiveness of these drugs are not well understood.
Active ErbB receptors phosphorylate each other on four to 12
tyrosine residues that serve as docking sites for recruitment
of diverse adaptor proteins containing Src homology domain 2
(SH2) and phosphotyrosine binding (PTB) domains (Jones
et al., 2006; Kaushansky et al., 2008; Schulze et al., 2005). Adap-
tors, and the proteins that bind to them, are often themselves
targets for phosphorylation by ErbB receptors or by cytoplasmic
kinases. This leads to assembly of large multiprotein ‘‘signalo-
somes’’ that transmit signals to downstream pathways including
the Raf-MEK-ERK (MAPK) and PI3K-Akt kinase cascades
(Yarden and Sliwkowski, 2001) and the actin cytoskeleton
(Hirsch et al., 2006) (Figure 1A). In cells exposed to exogenous
ligand, phosphorylation of receptors and adaptor proteins usu-
ally peaks within 10 min and then declines to prestimulus levels
1–2 hr later, thereby driving the immediate-early response.
Endocytosis and degradation of activated ErbB1 in the lysosome
plays the primary role in receptor adaptation (Sorkin and Goh,
2009), but internalization is less important for ErbB2-4 (Baulida
et al., 1996). Extensive evidence also points to a regulatory
role for protein tyrosine phosphatases (PTPs) in ErbB biology
(Table S3) (Tiganis, 2002), but it remains poorly understood
how receptors are controlled by a combination of changes in re-
ceptor conformation, oligomerization, phosphorylation/dephos-
phorylation, and localization. The classical view is that confor-
mational changes triggered by ligand binding drive the rapid
formation of tyrosine phosphorylated ErbB1 (ErbB1-pY) and
that the subsequent slower fall in ErbB1-pY levels involves reloc-
alization of receptors to phosphatase-rich intracellular compart-
ments, and attenuation of signaling via endocytic degradation
and the action of transcriptional feedback loops (Avraham and
Yarden, 2011). However, several experiments suggest a moreular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier Inc. 723
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Figure 1. Overview of Relevant RTK Signaling and Mathematical Models
(A) Schematic of phospho-sites assayed for ErbB1–3 and downstream proteins.
(B) Model M2: A simple biochemical scheme describing ErbB1 phosphorylation, dephosphorylation, and gefitinib binding.
(C) Model M3: A more detailed biochemical scheme describing ErbB1 conformational switching, binding of gefitinib, lapatinib, Shc, and phosphatase, and
competition between drug and ATP for binding to receptor.
(D) Key details and results from the various models. For model M3, parameter values for the median of 200 best fits are reported.
See also Tables S1 and S2.
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Modeling and Measuring ErbB1 Phospho-Dynamicsdynamic balance between activation and inactivation. For
example, treatment of cells with the potent pan-specific tyrosine
phosphatase inhibitor pervanadate causes large and immediate
increases in ErbB1-pY (and increased phosphotyrosine levels on
many other proteins) in the absence of added ligand (Ruff et al.,
1997), implying a requirement for phosphatases in opposing
receptor autoactivation. In addition, sequential exposure of cells
to ligand and then to a small molecule kinase inhibitor causes
phosphorylation to rise and then fall rapidly (Bo¨hmer et al.,
1995; Offterdinger et al., 2004). These data on turnover of tyro-
sine phosphates on ErbB1motivated us to perform amore quan-
titative and extensive study.
Here, we use a series of mathematical models (Figures 1B–1D)
and detailed time course data to address five unanswered ques-
tions about RTK phosphorylation: (1) What is the rate at which
tyrosine phosphorylation turns over on active ErbB1 receptors
under various conditions? (2) Is the rapid dephosphorylation an
artifact of drug binding? (3) Is the pool of ErbB1 subject to rapid
dephosphorylation the same pool that is active in signal trans-
duction, and, if so, what are the consequences of rapid phos-
pho-turnover for downstream signaling? (4) Do other ErbB
receptors and unrelated RTKs also exhibit rapid phospho-turn-
over? (5) What are the consequences of ErbB phospho-turnover
for the mechanisms of action of small molecule drugs that bind
ErbB receptors? The latter question seemed particularly inter-
esting because in vitro studies on anti-ErbB drugs have been
performed in the absence of phosphatases. We report that
ErbB1–3, the insulin-like growth factor 1 receptor (IGF1R), and
the fibroblast growth factor receptor 1 (FGFR1) cycle between
phosphorylated and unphosphorylated states on the time scale
of seconds and that phosphorylated forms of downstream
kinases such as ERK, Akt, JNK, and p38 also turn over rapidly.
We argue this is unlikely to be an artifact of drug binding. This
implies that a single RTK molecule is phosphorylated and de-
phosphorylated at least 100–1000 times over the course of an
1 hr immediate-early response. Rapid phosphorylation and
dephosphorylation of RTKs has significant implications for sig-
nalosome assembly and mechanisms of kinase inhibition.
RESULTS
Rapid ErbB1 Dephosphorylation Regardless
of Intracellular Localization
We studied ErbB receptor activation and inactivation in diverse
human tumor lines including transformed H1666, HeLa and
HepG2 cells and nontransformed MCF-10A cells. Serum
starved cells were treated with the ErbB1 ligand EGF and
receptor phosphorylation levels were then measured by using
phospho-site-specific antibodies in multiple formats including
immunofluorescence, western blotting and ELISA. We also
used a sandwich immunoassay that does not rely on having anti-
bodies selective for specific phosphorylation sites (the EpiQuant
assay from Millipore). In the EpiQuant method, proteolytic frag-
ments of receptor are captured on Luminex xMAP beads with
peptide-specific antibodies and modifications are detected
with pan-specific anti-phosphotyrosine antibodies. We obtained
nearly identical results with all assays except that the signal
to noise was greatest with the EpiQuant method (see theMolecSupplemental Experimental Procedures for details). In H1666
cells, levels of ErbB1-pY1173 (a binding site for the Shc adaptor
protein) (Jones et al., 2006) increased 5- to 10-fold within 10 min
of EGF addition and then fell with a half-life (t1/2) of 30 min,
returning to prestimulus levels by 2 hr, concomitant with a fall
in surface and total ErbB1 (Figure 2A and Figure S1A). However,
when cells were first stimulated with EGF and the clinical-grade
ErbB1 kinase inhibitor gefitinib (Karaman et al., 2008) was added
10min later, ErbB1-pY1173 levels declined exponentially to near
basal levels with t1/215 s (Figure 2B, red curve). No decrease in
total ErbB1 was observed (Figure 2C), consistent with the fact
that gefitinib blocks receptor internalization and degradation
(Nishimura et al., 2007). ErbB1 must therefore be dephosphory-
lated rather than degraded. Rapid ErbB1 dephosphorylation was
observed for all eight tyrosine residues on the ErbB1 tail for
which we could establish reliable assays (Figure 2D and Fig-
ure S1B) as well as after exposure of cells to different doses of
EGF (Figure S1C) or to other ErbB1 ligands (e.g., amphiregulin;
data not shown). While H1666 cells express only wild-type
ErbB1, rapid dephosphorylation of ErbB1 was also observed in
tumor cell lines that carry oncogenic, gefitinib-sensitizing muta-
tions (e.g., H3255 cells; data not shown) (Paez et al., 2004),
demonstrating that it is not unique to wild-type receptor. Finally,
ErbB1was rapidly dephosphorylated after treatment of cells with
the ErbB1 ATP-competitive kinase inhibitor erlotinib (data not
shown) and with canertinib (CI-1033; Figure 2B, orange curve),
a structurally different drug that covalently modifies the kinase
active site. From these data, we conclude that rapid ErbB1
dephosphorylation occurs at multiple phosphotyrosine residues,
under a wide variety of conditions and in the presence of kinase
inhibitors differing in chemical structures and mechanisms of
action.
The best-characterized PTP for ErbB1, PTP1B, resides in the
endoplasmic reticulum (ER) and interacts with receptors in peri-
nuclear ER compartments 30 min after EGF stimulation (Haj
et al., 2002). We therefore asked whether ErbB1 had to translo-
cate to the ER for efficient dephosphorylation. In EGF-stimulated
cells ErbB1 was found largely on the plasma membrane at
t = 2 min, in early endosomes by t = 10 min, and in late perinu-
clear endosomes by t = 30 min (Figure S1D). Receptor localiza-
tion was not observably altered by 1 min of gefitinib exposure at
t = 10 min (Figure S1D) and ErbB1-pY1173 turned over with
t1/2 15 s regardless of the interval between EGF and gefitinib
addition in a 2–30 min window (Figure 2E). We conclude that
ErbB1 is dephosphorylated rapidly following drug addition
regardless of cellular localization and thus, that receptors are
continuously accessible to potent PTPs.
Rapidly Dephosphorylated RTKs Are Active in Signaling
It is possible that only a subset of phosphorylated ErbB1 is
actively involved in signaling to downstream kinases and that
the pool of ErbB1 subject to rapid dephosphorylation is not the
relevant population for signal transduction. We therefore asked
whether rapid inactivation of EGF-stimulated ErbB1 by gefitinib
would propagate to receptors such as ErbB2 and ErbB3 that
are phosphorylated by ErbB1 in trans and also to cytosolic
kinases that transduce signals downstream of ErbB1 such
as ERK, Akt, JNK, and p38. In H1666 cells, we observed bothular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier Inc. 725
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Figure 2. ErbB1 Is Rapidly Dephosphorylated after Gefitinib Treatment
High-throughput fluorescence microscopy (HTM) measurements of total ErbB1 (cell surface plus internal) or ErbB1-pY1173 after ‘‘activation-inhibition’’
experiments where serum starved H1666 cells were stimulated with 100 ng/ml EGF followed by addition of 10 mM gefitinib or canertinib 10 min later (unless
otherwise noted). Pooled data are represented as mean ± standard deviation (SD) and normalized between 0 and 1.
(A) Receptor dynamics following EGF treatment. The two time courses were normalized separately and are not directly comparable.
(B–D) Activation-inhibition experiments as measured by HTM (B), western blotting (C), or ELISA (D). In (D), cells were treated with EGF for 10 min and gefitinib or
a DMSO control was then added for 1 or 15 additional min.
(E) Activation-inhibition experiment with gefitinib added 2, 10, or 30 min after EGF.
See also Figure S1.
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Modeling and Measuring ErbB1 Phospho-DynamicsErbB2-Y1221/1222 (a Shc binding site) and ErbB3-Y1289 (a
PI3K binding site) (Schulze et al., 2005) to be phosphorylated
10 min after EGF exposure and then rapidly dephosphorylated
upon subsequent addition of gefitinib (t1/2 15 s and 32 s,
respectively; Figure 3A). Shc1 was ErbB1-bound and phos-
phorylated following EGF addition but upon subsequent addition
ofgefitinib,Shc1-pY317was rapidlydephosphorylated (t1/226s)
and Shc1 dissociated from receptors (t1/2 14 s; Figure 3B and
Figure S2). These phenomena do not appear to be cell-type726 Molecular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier Ispecific: when ErbB1 and ErbB2 were assayed in MCF-10A,
HeLa and HepG2 cells we observed phospho-receptor half-lives
after gefitinib exposure to be 10–15 s in all cases (Figures 3C
and 3D). No correlation was observed between natural rates of
receptor inactivation, which varied from t1/2 10 min in HeLa
cells to 90 min in HepG2 cells, and the rate of phospho-
turnover after gefitinib addition, which was always fast. Net
receptor levels in the absence of drug are presumably set
by a dynamic balance between ligand binding/unbinding,nc.
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Figure 3. ErbB1 and Its Binding Partners Experience Rapid Phospho-Turnover across Cell Lines
(A) ErbB2 and ErbB3 phosphorylation measured by ELISA in H1666 cells in activation-inhibition experiments.
(B) Coimmunoprecipitation of ErbB1 and Shc1 in H1666 cells (left) and HTMmeasurements of Shc1 phosphorylation (right). The three Shc1 bands on the western
blot correspond to different isoforms.
(C and D) Reverse phase protein lysate array (RPPA) measurements of ErbB1 (C) and ErbB2 (D) phosphorylation in activation-inhibition experiments in three
additional cell lines.
See also Figure S2.
Molecular Cell
Modeling and Measuring ErbB1 Phospho-Dynamics
Molecular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier Inc. 727
Molecular Cell
Modeling and Measuring ErbB1 Phospho-Dynamicsphosphorylation/dephosphorylation and trafficking to and from
the plasma membrane.
The Akt and MAPK pathways are two critical kinase cascades
downstream of ErbB receptors. In both MCF-10A and H1666
cells, levels of Akt-pS473 increased after EGF exposure and
then fell rapidly upon subsequent addition of gefitinib (t1/2 100
and 60 s; Figure 4A). The same was true of ERK1/2-pT202/
Y204 in MCF-10A cells (t1/2210 s; Figure 4B, left). Moreover, la-
mellipod extension, an immediate-early EGF response involved in
cell migration (Segall et al., 1996), was also inhibitedwithin 40 s of
gefitinib addition (FiguresS3A–S3C).Weconclude that thepool of
ErbB1 receptors subject to rapid dephosphorylation is the pool
active in signaling to physiologically important downstream
processes and that Akt, ERK and lamellipod extension are them-
selves targets of potent negative regulation by phosphatases
(either directly or indirectly).
In EGF-treated H1666 cells, ERK dephosphorylation was
substantially slower after gefitinib treatment (t1/2 > 10 min; Fig-
ure 4B, right, and Figure S3D) than in MCF-10A cells, implying
either that ERK phosphatases are not as active as in MCF-10A
cells or that the activating signal sent by ErbB1 is longer lived.
To distinguish between these possibilities, EGF-stimulated
H1666 cells were treated with PD0325901, a non-ATP competi-
tive MEK inhibitor that locks the enzyme in a catalytically inactive
conformation. PD0325901 exposure resulted in rapid ERK
dephosphorylation (t1/2 40 s; Figure 4B, right) arguing that
potent ERK phosphatases are present in H1666 cells but that,
in the absence of phosphorylated receptor, proteins down-
stream of ErbB1 and upstream of ERK remain active for longer
than in MCF-10A cells. Raf kinase is mutated in H1666 (Pratilas
et al., 2008) but not MCF-10A cells and may be responsible for
prolonging ERK signaling in the former. When nine EGF-acti-
vated signaling proteins including receptor adaptors, kinases,
and transcription factors were examined in four cell lines we
consistently observed significantly more rapid dephosphoryla-
tion in the presence of gefitinib than in its absence; for example,
Akt-pS473 had a t1/2 4–120 min in the absence of gefitinib and
t1/240–130 s in its presence (heat maps are shown in Figure 4C
and time course data in Figure S3E). However, we also observed
that some EGF-induced modifications (S6-pS235/236 for ex-
ample) lasted long after receptors were inactivated. This reflects
the absence of potent S6 phosphatases in cells or a decoupling
between upstream and downstream signals (as observed with
ERK in H1666 cells) and points to an aspect of signal transduc-
tion dynamics that has not previously been studied.
The fact that multiple proteins activated by ErbB1 are subject
to as rapid dephosphorylation as ErbB1 after gefitinib addition
demonstrates that high phospho-turnover is not restricted to
drug-bound receptors. It is therefore difficult to argue that the
phenomenon is an artifact of drug binding. However, as a second
means to inactivate receptors we allowed ligand to dissociate
while blocking rebinding with the anti-ErbB1 receptor mono-
clonal antibody mAb225. With amphiregulin, a low-affinity
ErbB1 ligand that has a fast off rate (Neelam et al., 1998; Roep-
storff et al., 2009), ErbB1-pY1173 levels decayed exponentially
with t1/2 2 min (and with EGF, t1/2 10 min; Figure 5A). These
rates are substantially faster than the normal (net) rate of
receptor dephosphorylation (t1/2 > 1 hr for amphiregulin and728 Molecular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier I30 min for EGF in H1666 cells), arguing that in the absence of
drugs ErbB1 is rapidly inactivated by phosphatases when ligand
dissociates.
Finally, we asked whether RTKs other than ErbB receptors
exhibit rapid phospho-turnover. In MCF-10A cells stimulated
with IGF1 for 10 min we observed an increase in IGF1R-pY1131
and Akt-pS473 and a gradual decay subsequently. However,
when cells were treated with the IGF1R-selective kinase inhibitor
NVP-AEW541, both IGF1R and Akt were rapidly dephosphory-
lated (t1/2 80 s and 130 s, respectively; Figure 5B). Akt-pS473
also fell rapidly following addition of FGF1 and then the FGFR1-
specificdrugPD173074 (FigureS4; phospho-FGFR1 levels could
not be reliably measured). These data suggest that rapid
phospho-turnover may be a general feature of RTKs.
Quantifying ErbB1 Phospho-Turnover with Kinetic
Models
To explore the consequences of rapid phospho-turnover for
ErbB1 biochemistry we need models that can be compared
rigorously to data. Receptors and immediate-early signaling
molecules are relatively abundant and we therefore used mass
action kinetics as represented by networks of compartmental-
ized, ordinary differential equations (ODEs). By incorporating
data from in vitro studies and calibrating models against time
course data from cells we were able to estimate rates of ErbB1
phosphorylation and dephosphorylation under different condi-
tions (calibration in this context refers to repeated rounds of
fitting the model against experimental data while recording the
range of parameter values that return a good fit; see the
Supplemental Experimental Procedures, Computational Pro-
cedures S2 and S4 for details). More importantly, we could
instantiate different biochemical schemes in models and rigor-
ously determine which ones best represent the data.
In modeling ErbB receptors we must choose between simple
models that are not particularly realistic but for which available
data tightly constrain rate constants and uncertainty arises
only from experimental error (making the models identifiable),
andmore complex and realistic models that are non-identifiable.
To balance the competing demands of biological realism and
model identifiability, we constructed a series of models of
increasing complexity (M1–M3; Figures 1B–1D), guided by the
principle that for any specific set of data, the simplest model
compliant with themeasurements is generally the best. The least
complex ‘‘model’’ (M1) lacks mechanistic detail and assumes
exponential decay from peak phospho-ErbB1 levels at t =
10 min; the phosphorylation half-lives reported above were
calculated using this model. M1 yielded a net ErbB1-pY1173
dephosphorylation rate constant of 0.02/min in cells treated
with EGF alone and7/min in cells subsequently exposed to ge-
fitinib. Using measured values of 105 ErbB1 molecules per
H1666 cell and maximal fractional phosphorylation of 0.4 (see
the Supplemental Experimental Procedures, Computational
Procedure S1 for details), we computed that approximately ten
net receptors are dephosphorylated per cell per second with
EGF alone (at t = 10 min) versus 53 103 after gefitinib treatment.
Conversely, maintenance of high net levels of ErbB1 phosphory-
lation in the absence of gefitinib requires rapid receptor
rephosphorylation.nc.
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Figure 4. Downstream Proteins Also Exhibit Rapid Phospho-Dynamics
(A and B) HTM measurements of Akt (A) and ERK (B) phosphorylation after treatment of MCF-1A and H1666 cells with EGF and then 10 mM gefitinib or 1 mM
PD0325901, a MEK inhibitor
(C) Heat map of approximate half-lives (calculated from t = 10 min) for dephosphorylation of various proteins as measured by RPPA in activation-inhibition
experiments with 10 mM gefitinib added 10 min after EGF in four cell lines. Atypical means that phosphorylation levels rose after 10 min of EGF exposure and the
maximumwas not reached by the time of drug addition: light gray, protein not phosphorylated by 10min EGF and no change in phospho-signal with gefitinib; dark
blue, no decline in phospho-signal over the time measured; light blue, late decline. N.D. (dark gray) indicates that the signal was not detected.
See also Figure S3.
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BErbB1 Dynamics Following Ligand WashoutA
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Figure 5. Activation-Inhibition Experiments with Ligand Washout and an IGF1R-Specific Inhibitor
(A) HTM measurements of ErbB1-pY1173 in H1666 cells. After 10 min exposure to 100 ng/ml EGF or 177 ng/ml amphiregulin (AR) (both 16 nM), ligand was
removed and replaced with conditioned media plus mAb225.
(B) IGF1R-Y1131 and Akt-S473 dephosphorylation as measured by western blotting in MCF-10A cells after 100 ng/ml IGF1 stimulation followed by addition of
20 mM NVP-AEW541 (an IGF1R-specific kinase inhibitor). Quantification was performed by background subtraction and normalization to GAPDH.
See also Figure S4.
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tion (model M2) encompasses receptors cycling between
unmodified and modified (phosphorylated) states, both of
which can be bound by drug (Figure 1B; see the Supplemental
Experimental Procedures, Computational Procedure S2 for
details). M2 involves a separation of time scales that focuses
on the 10 min period after gefitinib addition and ignores initial
receptor activation prior to drug exposure as well as slower
processes such as receptor degradation. Because ErbB1 is
expressed at much higher levels than ErbB2-4 in H1666 cells
(Supplemental Experimental Procedures), M2 includes only
ErbB1. Binding of gefitinib to ErbB1 is assumed to be indepen-
dent of receptor phosphorylation and in quasi-equilibrium,
a reasonable assumption since drug-receptor interactions are
likely diffusion limited (Northrup and Erickson, 1992). Gefitinib
binds and inactivates receptors by displacing ATP, which is
present implicitly. It can be shown analytically that M2 is identifi-
able for the phosphorylation and dephosphorylation rate
constants (k1 and k1, respectively) and for the apparent associ-
ation constant for gefitinib binding (KeqG).
To calibratemodel M2we collected a detailed dataset in which
ErbB1-pY1173 levels were measured with a high sampling rate
in H1666 cells exposed to EGF and subsequently to 1–20 mM
gefitinib at t = 10 min (Figure 6A). At 10–20 mM gefitinib, ErbB1-
pY1173 exhibited t1/2 5 s and near-complete receptor dephos-
phorylation within 20 s, as described above. However, when
gefitinib was added at 1 mM results were qualitatively different:
ErbB1-pY1173 levels fell rapidly at first but then plateaued at
50% of initial levels. When M2 was calibrated against data
from cells treated with 1 or 10 mM gefitinib it accurately predicted
the effects of exposure to 5 or 20 mMgefitinib (Figure S5A; rmsd =
0.04). Calibration across all data yielded k14.5/min (s = 1.6), k1730 Molecular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier I8/min (s = 0.7) and KeqG1.3 mM1 (s = 0.9) (Figure 6B). These
numbers are consistent with in vitro estimates for k1, which range
from1.5/min to20/min (Qiu et al., 2009; Yun et al., 2008). Our
estimate for KeqG reflects competition with intracellular ATP and
the Cheng-Prusoff equation yields a Kd 2.5 nM, close to the in-
vitro value of 1 nM (Karaman et al., 2008). Thus, rate constants
estimated forM2fitwell with previous data obtained fromdetailed
in vitro studies implying that M2, for all its simplifications, is
a reasonable representationof ErbB1-Y1173phospho-dynamics.
By assuming phosphorylation/dephosphorylation events to be
Poisson-like processes and performing Monte Carlo-based
simulations, we estimate the mean lifetime of unmodified ErbB1
in the presence of EGF to be 14 s and the phospho-state to be
8 s (modelM2-MC; FiguresS5BandS5C; see theSupplemental
Experimental Procedures, Computational Procedure S3 for
details). The mean lifetime of the unmodified state increases to
30 swith 1 mMgefitinib present and190 s with 10 mMgefitinib.
Model M3: A Model for Comparing Gefitinib
and Lapatinib
The data described above pertain to drugs such as gefitinib that
are thought to bind to ErbB1 in an active conformation. However,
a second class of drugs has been developed that binds to inac-
tive receptors. In the case of lapatinib, a drug of this class that
has been successful as a clinical agent, tight binding is also
observed to ErbB2 (Kd 5 nM for both receptors (Karaman
et al., 2008; Wood et al., 2004). When we compared ErbB1-
pY1173 phospho-dynamics in EGF-treated cells exposed to
gefitinib or lapatinib, we observed two significant differences.
First, after exposure to lapatinib at or below the IC50 concentra-
tion (1 mM) phospho-ErbB1 levels fell significantly slower than
with gefitinib (t1/2 8 min versus 5 s with gefitinib), but completenc.
A B C
D E
Figure 6. Model M2 Provides Estimates for Rate Constants and Model M3 Allows for Analysis of Phospho-Dynamics after Drug Treatment
ErbB1-pY1173 in H1666 cells was measured in activation-inhibition experiments by HTM.
(A) Dose-response with gefitinib (circles). M2 simulations using the median of the estimated parameter values are shown as solid curves.
(B) Estimates for kinetic parameters using aMonte Carlo simulation based on fitting with 103 randomly selected data values within the experimentally determined
range.
(C) Dose-response with lapatinib.
(D) M3-based simulations (the best 100 model fits are shown as overlapping lines) and experimental data (individual data points, squares, are averages of
replicate measurements made on the same day and error bars were calculated using an error model). The t = 0 data point was added to force model pre-
equilibration; the model steady state is representative of EGF treatment alone and model assumptions begin to break down after 30 min (gray).
(E) Simulations (lines) and experimental data (squares) for individual or combination treatment with 10 mMgefitinib and 100 mMpervanadate. Data for the individual
treatments were used during fitting whereas the combination was not.
Data in (A), (D) and (E) were normalized as described in the Supplemental Experimental Procedures, Computational Procedure S4. See also Figure S5.
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In contrast, treatment of cells with gefitinib near that drug’s IC50
value (also1 mM) resulted in rapid but partial receptor inhibition
(Figures 6A and 6D).
To compare lapatinib and gefitinib we created model M3, rep-
resenting a consensus view of drugmechanism of action, as well
as a series of variant models (M3-V1, V2, and V3) that explored
alternative biochemical hypotheses (see the Supplemental
Experimental Procedures, Computational Procedure S4 for
details). The parental M3model includes a switch between active
and inactive ErbB1 conformations, stronger binding of ATP and
gefitinib to active ErbB1, and preferential binding of lapatinib to
inactive ErbB1 in a manner that blocks the transition to an activeMolecconformation (Johnson, 2009; Wood et al., 2004) (Figure 1C).
Finally, we assumed phosphatases to associate reversibly with
receptors and Shc to bind reversibly to ErbB1-pY1173, protect-
ing phosphotyrosine residues from phosphatases when bound.
Because the relative affinities of ATP and gefitinib for active
versus inactive ErbB1 are unknown, they were considered as
adjustable parameters whose values were estimated by calibra-
tion. Implementing these assumptions, with other details similar
to those of M2, resulted in a model with 47 ODEs and 21 param-
eters. Data for M3 calibration consisted of 12 sets of ErbB1-
pY1173 dynamics in cells treated first with EGF for 10 min and
then with 0.25–20 mM gefitinib or 0.5–10 mM lapatinib (a subset
of the data is shown in Figure 6D and the entire data set isular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier Inc. 731
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some parameters were constrained within ranges consistent
with in vitro observations. M3 is expected to return faster rate
constants for ErbB1 phosphorylation and dephosphorylation
than M2 because drug and ATP compete for receptor binding
and phosphatases compete with adaptor proteins for interaction
with phosphotyrosines. Indeed, estimated rate constants were
>10-fold higher in M3 than M2 (Figure 1D and Figure S5D).
M3 shows receptors to undergo at least 150 phosphorylation/
dephosphorylation cycles per hour with saturating EGF and 30
cycles per hour with saturating gefitinib. Thus, treating cells
with 10 mM gefitinib plus pervanadate, a pan-specific PTP inhib-
itor that irreversibly oxidizes a catalytic cysteine (Huyer et al.,
1997), should cause an initial drop in ErbB1-pY due to rapid ge-
fitinib binding and then a steady rise as drug dissociates and
receptors become phosphorylated. This is precisely what we
observed in cells (Figure 6E, cyan curves and squares). When
cells were exposed to pervanadate in the absence of EGF and
gefitinib, ErbB1-pY also rose to high levels (Figure S5E)
(Amanchy et al., 2005). To determine whether this involved an
autocrine ligand (or residual ligand from media) cells were
treated with saturating mAb225 anti-ErbB1 antibody for 2 hr
prior to pervanadate exposure, with no observable reduction in
ErbB1-pY accumulation (Figure S5E). These data confirm
model-based predictions, suggesting that even receptors lack-
ing bound ligand are rapidly phosphorylated in the presence of
gefitinib and absence of antagonizing phosphatases.
A Kinetic Scheme for ErbB1 Binding to Small Molecule
Drugs
WithM3we sought tomove beyond an analysis of rate constants
and investigate mechanisms of drug-receptor interaction. This
necessitated estimates for rates of interconversion among
different drug-receptor complexes (a measure of reaction fluxes)
which in turn required the development of a new in silico labeling
method for calculating fluxes from calibrated, nonidentifiable
ODE networks (T.M., unpublished data). With these methods in
hand we asked why exposure of cells to lapatinib results in
much slower ErbB1 dephosphorylation than exposure to gefiti-
nib. Analysis of M3 by in silico labeling showed initial ErbB1
phospho-dynamics in the presence of 10 mM lapatinib to be
determined by the relatively slow conversion of receptor to an
inactive conformation (Figure 7A): it took 20 min for active
receptors to switch to the inactive conformation, and receptors
subsequently bound lapatinib in 30 s (these ‘‘transition times’’
represent the time required for 50% of receptors to switch from
one state to another at least once). In contrast, initial phospho-
dynamics in the presence of gefitinib were determined by fast
binding of drug to the active conformation and rapid dephos-
phorylation (11 s). Thus, while our model is consistent with
in vitro data showing that lapatinib binds more slowly to ErbB1
than gefitinib (the on-rate for binding of gefitinib to the active
ErbB1 conformation was 12 nM/min and the on-rate for
lapatinib binding to the inactive conformation was 1.5 3
104 nM/min), the rate-limiting step in cells for ErbB1 dephos-
phorylation in the presence of lapatinib is an active-to-inactive
conformational transition that is one to two orders of magnitude
slower than drug binding.732 Molecular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier IWhy does exposure to low-dose lapatinib result in complete
receptor inhibition but low-dose gefitinib does not? From M3
we estimate that ATP binds 5 3 104-fold less strongly to inac-
tive than active ErbB1, consistent with a difference in the shape
of the catalytic pocket (Johnson, 2009). Consequently, drugs
such as lapatinib that associate with the inactive conformation
encounter much less competition from intracellular ATP than
drugs such as gefitinib. Moreover, M3 predicts very slow
unbinding of lapatinib (20 hr), essentially locking the receptor
in the inactive state (Figure 7A). In contrast, low-dose gefitinib
incompletely inhibits ErbB1 because the forward rate of phos-
phorylation by drug-free receptors is approximately balanced
by a reverse reaction in which drug-free and drug-bound recep-
tors are dephosphorylated. Thus, incomplete inhibition reflects
the fact that active receptors continually reform, in accordance
with results obtained from pervanadate treatment (Figure 6E).
Simulations provided a further insight: differences between gefi-
tinib and lapatinib can only be explained if ErbB1 phospho-turn-
over is rapid. If the rate of turnover is steadily decreased while
fixing the ratio of the phosphorylation and dephosphorylation
rate constants, gefitinib and lapatinib become more and more
similar in their effects until they are indistinguishable 20-fold
below their nominal values at 2.5/min (Figure 7B).
Inspection of our kinetic scheme reveals a number of unex-
pected features. For example, M3 predicts the transition time
from inactive to active ErbB1 (dashed box in Figure 7A) to be
70 min in the presence of gefitinib and >10 days in the pres-
ence of lapatinib. Since neither form of ErbB1 is drug-bound,
this result seems paradoxical. However, fluxes between states
are functions not only of rate constants, but also of reactant
concentrations: at the quasi-steady state achieved 3 hr after
exposure to drug, the concentration of inactive and unbound
ErbB1 is much lower in the presence of lapatinib than gefitinib
(0.03% versus 1% of total receptors), even though the rate
constant for conversion to the active conformation is the same.
Thus, relative concentrations explain the long time required for
transition of receptors to an active conformation when lapatinib
is present. Gefitinib is generally assumed to primarily bind and
inhibit an active ErbB1 conformation (Yun et al., 2007). Consis-
tent with this, M3 predicts that gefitinib binds to active ErbB1
150-fold more avidly than to the inactive conformation (Kd
1 nM versus 165 nM). Nonetheless, simulation shows that
complexes between gefitinib and inactive ErbB1 are 4-fold
more abundant than complexes between gefitinib and active
ErbB1 (at 10 mM gefitinib; Figure 7C). How can this be? Analysis
of M3 suggests that it arises because competition between
micromolar drug and millimolar intracellular ATP dominates the
distribution of drug-receptor complexes. Much less competition
from ATP for binding to inactive receptor conformations permits
significant gefitinib association in the face of a high binding
constant. If this hypothesis can be confirmed for other receptors,
then it has clear implications for the design of high potency
drugs.
Testing Variant Models and Model Predictions
The strength of our conclusions necessarily depends on the
accuracy of hypotheses made during model construction,
including the assumptions that receptors not bound to drugnc.
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Figure 7. A Kinetic Scheme for Comparing
Gefitinib and Lapatinib
(A) Transition times are indicated for the best fit of
M3 with 10 mM gefitinib (red) or lapatinib (green),
representing the time for 50% of receptors to
switch at least once to the other state. The Kds for
gefitinib binding to the active conformation and
lapatinib binding to the inactive conformation were
set at in vitro values, while the Kd for gefitinib
binding the inactive conformation was fitted.
Transition times are dependent on species con-
centrations; only a subset of possible transitions
is shown (e.g., the gray arrow indicates that gefi-
tinib can also bind non-phosphorylated receptors).
A, active conformation; I, inactive conformation.
(B) ErbB1 phosphorylation following 10mM gefiti-
nib or lapatinib exposure assuming progressive
decreases in phosphorylation (k1) and dephos-
phorylation (k1) rates from best fit values (dashed
black). The k1/k1 ratio was held constant, with k1
ranging from 209/min to 0.3/min and k1 from
38/min to 0.06/min, and the predrug steady-state
phosphorylation levels were rescaled to 40%.
(C) M3 prediction of the fraction of gefitinib-bound
receptors in the active or inactive conformation
(normalized by the total number of receptors)
following addition of 10mM gefitinib at t = 10 min.
(D) HTM measurements of ErbB1-Y1173 phos-
phorylation in MCF-10A cells treated with EGF for
1 min and subsequently with gefitinib.
(E) M3 prediction and ErbB1-pY1173 measure-
ments in H1666 cells of combination treatment
with gefitinib and lapatinib (data for EGF treatment
alone is dotted since M3 does not capture this
behavior). The data shown are representative of
experiments with various drug concentrations.
See also Figure S6.
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does not significantly bind to ErbB1 in the active conformation.
We tested these assumptions by asking whether variant models
could be fitted to the data (Figure 1D). Model M3-V1 assumes
that only drug-bound receptors are dephosphorylated, and
model M3-V2 assumes that gefitinib and lapatinib both bind
only to the active conformation of ErbB1. When a multistart
search was performed across a large range of values for allMolecular Cell 43, 723–737, Smodel parameters and fits to data were
calculated, M3-V1 and M3-V2 were re-
jected with high confidence relative to
the parental model M3 (p < 1010).
Furthermore, if we allowed lapatinib to
choose between the two conformations
using model M3-V3, negligible binding
was observed to the active conformation.
Two interesting M3 predictions with
respect to ErbB1 phospho-dynamics
were testable in cells. First, low-dose ge-
fitinib should result in a state of chronic
sub-maximal receptor activity. Consis-
tent with this, we observed that additionof 0.5–1 mM gefitinib to MCF-1A or H1666 cells 1–2 min after
EGF stimulation led to fractional ErbB1-Y1173 phosphorylation
that was sustained for many hours (Figure 7D and Figure S6A).
Under these conditions, ErbB1 was not detectably degraded
and did not translocate to late endosomes as usual following
EGF treatment (Figures S6B and S6C). Similar results were ob-
tained when cells were pretreated with gefitinib for 1 hr before
addition of EGF (Figure S6D). Thus, one consequence of rapideptember 2, 2011 ª2011 Elsevier Inc. 733
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presence of subsaturating gefitinib appears to be the generation
of a pool of receptors whose level or rate of phosphorylation is
insufficient to trigger normal adaptation or degradation. More-
over, the phenomenon occurs at drug concentrations approxi-
mating the maximum serum concentration in human patients
(0.5-1 mM) (Baselga et al., 2002).
A second model prediction is that gefitinib should interfere
with the ability of low-dose lapatinib to promote complete
ErbB1 dephosphorylation. Interference is predicted to be subtle
but could be confirmed experimentally. When gefitinib and lapa-
tinib were simultaneously added to EGF-stimulated cells, ErbB1
dephosphorylation occurred in two phases: receptors were first
rapidly dephosphorylated as a consequence of gefitinib binding
to receptor in the active conformation and then were slowly in-
hibited as a consequence of lapatinib inducing a switch to the
inactive conformation (Figure 7E). The latter step is slower in
the presence of both drugs than lapatinib alone, suggesting
that gefitinib interferes with lapatinib action by holding some
receptors in the active state.
DISCUSSION
Ligand binding activates RTKs, resulting in their phosphorylation
on multiple tyrosine residues that serve as binding sites for cyto-
solic adaptor proteins. Association of adaptors (and other
proteins) promotes assembly of large multiprotein complexes
that initiate immediate-early signaling. In this paper we quantify
rates of turnover on the phosphotyrosine sites of activated RTKs
and investigate the consequences for signaling and receptor
inhibition by drugs. Our approach combines mathematical
modeling, clinical-grade drugs and time course data on five
RTKs, their adaptors and downstream signaling proteins in
four cell lines. We find that very rapid turnover of activating sites
of phosphorylation is a common property of RTKs and the down-
stream kinases they control. The classical view holds that RTKs
such as ErbB1 rapidly acquire kinase activity upon ligand binding
and are inactivated over 30–90 min by a combination of dephos-
phorylation, internalization, degradation and negative feedback
(Avraham and Yarden, 2011). However, ErbB1 can be rapidly de-
phosphorylatedwhen kinase activity is acutely inhibited by drugs
(Bo¨hmer et al., 1995; Offterdinger et al., 2004), and inactivation of
tyrosine phosphatases using pervanadate has long been known
to cause receptor phosphorylation (Ruff et al., 1997). These data
imply rapid phospho-turnover of ErbB1 and chronic negative
regulation by tyrosine phosphatases. Our analysis agrees
with and extends these observations. We find that the half-lives
of phosphorylated tyrosine residues on ErbB receptors are
10–30 s (and possibly much shorter) and thus that receptors
cycle between phosphorylated and unphosphorylated states at
least 100–1000 times over the course of a typical immediate-
early response. Phosphates on downstream signaling kinases
(typically on serine and threonine residues involved in activation)
also exhibit rapid turnover.
Our studies address three questions left unresolved by earlier
experiments: (1) is rapid ErbB1 dephosphorylation an artifact of
drug binding, (2) is the pool of ErbB1 subject to rapid phospho-
turnover the same pool active in signal transduction, and (3) is734 Molecular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier Irapid phospho-turnover observedwith other RTKs? Several lines
of evidence argue that the phospho-turnover we observe is
not simply an artifact of drug binding. First, when EGF-treated
cells are exposed to the ErbB1-selective inhibitor gefitinib,
rapid dephosphorylation occurs on many proteins that do not
themselves bind drug, including other RTKs (e.g., ErbB2 and
ErbB3), adaptor proteins (e.g., Shc) and downstream kinases
(e.g., Akt, ERK and p38). It is highly improbable that changes in
ErbB1 induced by drug binding could affect these other proteins,
several of which do not interact with ErbB1 directly. Moreover,
rapid dephosphorylation is observed following simple ligand
washout and for a range of small molecules and antibody drugs
that bind to ErbB1 in different ways. Finally, analysis of a compu-
tational model in which we assume rapid dephosphorylation to
be restricted to drug-bound receptors is rejected with high prob-
ability based on a comparison to data.
The fact that ErbB1 inhibition results in rapid dephosphoryla-
tionofdownstreamsignalingproteinsandcessationof lamellipod
extension (an immediate-early response to EGF) demonstrates
that the pool of ErbB1 subject to rapid phospho-turnover is the
pool active in signaling. Moreover, rapid phospho-turnover is
not restricted to ErbB1 and the same phenomenon can be
observed (or inferred) for EGF-activated ErbB2 and ErbB3, and
for IGF1R and FGFR1. From these and other data we conclude
that rapid phospho-turnover is a normal feature of RTK biology
that occurs over a wide range of ligand concentrations in trans-
formed and non-transformed cells. Fast cycling between phos-
phorylated anddephosphorylated states has also beenobserved
for high affinity IgE receptors, which normally mediate inflamma-
tory reactions including allergic responses (Mao and Metzger,
1997). We hypothesize that many receptor-mediated events at
the plasma membrane exhibit high dynamicity, potentially allow-
ing cells to respond rapidly to changes in the extracellular
environment.
Consequences of Phospho-Turnover for Signal
Transduction
Rapid turnover of tyrosine phosphates on RTKs implies rapid
assembly and disassembly of signaling complexes, since
binding of SH2 and PTB domains to tyrosine phosphates has
been shown to protect modified residues from phosphatases
(Brunati et al., 1998). This hypothesis is consistent with data on
binding affinities and protein abundance. We measured a similar
concentration of ErbB1 and the Shc1 p52 isoform in H1666 cells
(see the Supplemental Experimental Procedures), and assuming
a Shc1 affinity of 150 nM (Jones et al., 2006), model M3 pre-
dicts that in the presence of saturating ligand 15% of ErbB1
is Shc-bound with a t1/2 2 s for the complex (a finding consis-
tent with immunoprecipitation data). Short half-lives should
result in shuttling of SH2 and PTB-containing adaptors among
binding sites on the same or neighboring RTKs, a situation anal-
ogous to the shuttling of G protein subunits among seven trans-
membrane domain receptors (Linderman, 2009).
Shuttling of adaptor proteins among signaling complexes has
significant implications for modeling ‘‘combinatorial complexity’’
(Hlavacek et al., 2003). Simple enumeration of all oligomeric,
phospho and assembly states of ErbB1 suggests at least 107
biochemically distinct species (Schulze et al., 2005), but it isnc.
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since the number of states exceeds the number of receptors
(104–106molecules/cell) each statemust have very low fractional
occupancy, which is expected to result in large stochastic fluctu-
ations. However, if assembly states interconvert on time scales
that are rapid (seconds) relative to the time scales of imme-
diate-early signaling (tens of minutes), RTKs can be modeled as
having a time-averaged quasi-static state structure that involves
considerably fewer states. Similar mathematical approximations
have recently been described to model complex patterns of
multi-site phosphorylation (Thomson and Gunawardena, 2009).
From our data, it follows that RTKs and cytosolic kinases such
as Akt, ERK, and p38 are all antagonized by potent phospha-
tases. Theoretical studies suggest phosphatases to be among
the most critical and least understood regulators of signal
transduction (Heinrich et al., 2002). In the case of ErbB1, phos-
phatases appear to be active in multiple subcellular compart-
ments including the plasma membrane. Biochemical fraction-
ation and cloning experiments have identified multiple enzymes
with the potential to antagonize ErbB1 kinase activity (Table S3)
(Tiganis, 2002), some of which have been implicated in receptor
activation by UV or free radicals (Xu et al., 2006). The connection
between the rapid phospho-turnover we observe and net decline
in receptormodification that occurs on a longer time scale during
receptor adaptation remains to be elucidated: we measure
equally rapid phospho-turnover of ErbB1 and ErbB2 in cells in
which the natural half-life of phosphorylated receptors (in the
absence of drug) varies between 12 and 90 min. Perhaps rapid
phospho-turnover is involved in setting the sensitivity of RTK
signaling, by loose analogy to the zero-order sensitivity observed
with cycling enzymatic systems (Goldbeter and Koshland, 1981).
The turnover of upstreamanddownstreamsignalingmolecules
is not always tightly linked:we find that rapid receptor inactivation
has a variable effect on the rate of dephosphorylation of a dozen
downstream proteins across a panel of four cell lines. In the case
of phospho-ERK for example, rapid decay is observed after
ErbB1 inhibition in MCF-10A cells, but dephosphorylation is
slower in H1666 cells. H1666 cells indeed contain active ERK-
directed phosphatases, since pharmacological inhibition of the
kinase for ERK (MEK) causes rapid ERK dephosphorylation.
Instead, it seems that one or more proteins linking ERK to
ErbB1 (e.g., Ras or Raf) have longer-lived active states in H1666
cells. It will be worth investigating this phenomenon in greater
detail to see if it might play a role in oncogenic transformation.
Quantifying Phospho-Turnover Rates and Investigating
Consequences for RTK Pharmacology
Rates of receptor phospho-turnover in cells are not directly
observable using existing methods but they can be inferred by
creatingmodels of receptor biochemistry, calibrating themodels
to experimental data and subjecting model-based predictions
to empirical tests. In this paper, we use a succession of models
differing in complexity to reconcile the competing demands of
identifiability (possible with simple models) and biochemical
reality (which is complex). Rate constants estimated using
different models vary in magnitude, with an increase in the
number of assumed biochemical states generally resulting in
faster rates (hence the ranges cited in Figure 1D). Since modelsMolecM1–M3 are not particularly detailed in comparison to the actual
biochemistry or even to models we and others have published
previously (e.g., Blinov et al., 2006; Chen et al., 2009), our esti-
mated rate constants represent lower bounds; it is probable
that actual rates are higher.
The real value of kinetic modeling is not to derive rate
constants but to understand the logic and dynamics of complex
multi-step processes, in the current case the mechanisms of
action of gefitinib and lapatinib, exemplars of two classes of
small molecule ErbB1 kinase inhibitors.We have analyzedmodel
M3 using a newly developed method of in silico labeling that
makes it possible to estimate flux-based transition times
between states in the face of parameter non-identifiability. Flux
estimates aremore tightly constrained than estimates of elemen-
tary rate constants, probably because they are computed from
ratios of correlated parameters (Chen et al., 2009). In vitro, gefi-
tinib binds rapidly and reversibly to ErbB1 in an active conforma-
tion (Yun et al., 2007) whereas lapatinib binds to an inactive
conformation and acts as though it is irreversible (Wood et al.,
2004). Experimentally we observe two significant differences
between gefitinib and lapatinib in cells: ErbB1 dephosphoryla-
tion in the presence of gefitinib is rapid but incomplete at clini-
cally accessible doses (<2 mM for cells with wild-type ErbB1)
and results in chronic receptor activation. Lapatinib inhibits
receptors >20-fold more slowly but it eventually results in
complete inhibition even at low doses. Sustained receptor acti-
vation in the presence of gefitinib is a direct result of rapid phos-
pho-turnover, competition from millimolar intracellular ATP and
rapid reformation of active receptors. Indeed, model analysis
suggests that competition fromATP is so significant in themech-
anism of drug action, that complexes between inactive ErbB1
and gefitinib are 4-fold more abundant than between active
ErbB1 and gefitinib (at 10 mM gefitinib), even though gefitinib
binds 150-fold more avidly to active ErbB1.
In the case of lapatinib, we hypothesize that slow inactivation
of receptor is dominated not by the on-rate for binding to inac-
tive ErbB1 as proposed previously (Wood et al., 2004), even
though it is 105 slower than for gefitinib, but instead by an
active-to-inactive conformational transition that is one to two
orders of magnitude slower again. M3 predicts that it takes
20 min for half of all active receptors to switch to the inactive
conformation, and that these receptors then bind drug in
30 s (at 10 mM lapatinib). Once lapatinib is bound, switching
back to the active conformation is very slow (>10 days), not
simply because the rate constant for lapatinib unbinding is
low, but because the concentration of inactive and drug-
unbound ErbB1 is low. Thus, in the presence of gefitinib, the
transition time from the inactive to active state is 70 min,
even though the rate constant for conformational switching for
unbound ErbB1 is unaffected by drug. These observations
make clear the value of computing fluxes that account for both
rate constants and species concentrations.
Conclusions
The accuracy of our scheme for binding of gefitinib and lapatinib
to ErbB1 necessarily depends on the validity of our models. This
might appear to be a vulnerability peculiar to our computation-
driven approach, but we have argued that a tight link betweenular Cell 43, 723–737, September 2, 2011 ª2011 Elsevier Inc. 735
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studies (Spencer and Sorger, 2011). Mathematical modeling
simply serves to make hidden assumptions explicit. Indeed,
widely cited in vitro biochemical parameters for anti-ErbB drugs
were calculated using arithmetic formalisms that also make
strong assumptions about quasi-static states (Chen et al.,
2010). We cannot prove that our models are uniquely correct or
that we have fully accounted for experimental uncertainty and
error, but computational models have the merit that they can be
readily and transparentlymodified asnew ideas emerge, allowing
old and new hypotheses to be rigorously compared. Arguments
in favor of the conclusions presented here include the following:
(1) enzymatic and drug binding parameters estimated using
models and cell-based data are largely consistent with in vitro
measurements and those discrepancies that exist can be ratio-
nalized, (2) fundamental conclusions are not particularly sensitive
to model topology, with three distinct formulations (M1–M3) all
yielding similar conclusions about phospho-turnover, and (3)
several variant models that explore alternative hypotheses can
be rejected on the basis of comparison to data. The conclusions
in this paper also have clear implications for drug development.
They suggest that in the case of kinaseswith slow active-to-inac-
tive transitions it is significantly more important to optimize
binding to inactive than active conformations.When these transi-
tions are more rapid or ATP is able to bind appreciably to both
conformations, it should be possible to usemodeling to compute
tradeoffs involved in developing drugs that bind to various kinase
states with differing affinities.
EXPERIMENTAL PROCEDURES
Cell Lines and Materials
H1666, MCF-10A, HeLa, and HepG2 cells were cultured using standardmedia
and protocols. Recombinant human EGF, IGF1, and FGF1 were purchased
from PeproTech, amphiregulin from R&D Systems, canertinib fromWuXi Phar-
maTech, gefitinib and lapatinib from LC Laboratories, NVP-AEW541 from
Cayman Chemical, PD173074 from Stemgent and PD0325901 from Selleck.
Mouse mAb225 was a gift from J. Spangler and D. Wittrup. Pervanadate
was prepared bymixing equal amounts of activated Na3VO4 and H2O2 (Sigma)
in water 10 min before use. Biochemical assays were performed using stan-
dard protocols that are described in the Supplemental Experimental
Procedures.
Mathematical Modeling
M1, M2, and M2-MC were formulated and analyzed within Mathematica as
ordinary differential equations or as stochastic processes. The MATLAB
toolbox PottersWheel (Maiwald and Timmer, 2008) was used to perform differ-
ential equation modeling of M3 and to apply Maximum-Likelihood parameter
calibration based on experimental data. All models are described in detail in
the Computational Procedures section of the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, three tables, and five model files and can be found with this article
online at doi:10.1016/j.molcel.2011.07.014.
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